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Background: Plaque disruption followed by its healing process is supposed one of major mechanisms for atherosclerosis progression. Indeed, 
there is a pathological evidence of repeated plaque rupture and healing at the site of significant stenosis. We examine the change in the luminal 
stenosis at the site of silent plaque disruption and analyze its associated factors in the era of optimal medical therapy.
methods: Among 144 consecutive patients who received coronary angiography and angioscopy that identified silent plaque disruption from August 
2007 to December 2010 (baseline), 36 patients who had repeated coronary angiography later (follow-up) were included for analysis. Silent plaque 
disruption was defined as the plaque with thrombus detected by angioscopy in the non-culprit segments of coronary arteries. Diameter stenosis of 
the site with silent plaque disruption was angiographically measured at baseline and that of the same site at follow-up was also measured; and their 
difference was defined as stenosis change.
results: Statin was used in 89% of study patients, and serum low-density lipoprotein cholesterol level was 91±21mg/dL. The diameter stenosis at 
silent plaque disruption decreased significantly from baseline to follow-up (32±14 vs. 27±14, p<0.001); and the stenosis change was −5.6±7.9%. 
High-density lipoprotein cholesterol was significantly associated with stenosis change (r=−0.51, p=0.001) and was the only factor significantly 
associated with stenosis change by multivariate linear regression analysis (B=−0.34, p=0.001).
conclusions: In the era of optimal medical therapy with statin, the site of silent plaque disruption showed significant regression of luminal 
stenosis. However, the serum level of high-density lipoprotein cholesterol was negatively associated with the stenosis change at the site of silent 
plaque disruption.
